Profile: Allergan plc (AGN)
28 Jul 2015
Allergan plc, formerly Actavis plc, is a pharmaceutical company. The Company is focused on developing, manufacturing and commercializing pharmaceuticals, generic and over-the-counter medicines and biologic products for patients around the world. It markets a portfolio of products that provide treatments for the central nervous system, eye care, medical aesthetics, gastroenterology, women's health, urology, cardiovascular and anti-infective therapeutic categories, and operates global generics business, providing patients around the globe with increased access to medicines. The Company is engaged in research and development, with development pipelines in the pharmaceutical industry and a position in the submission of generic product applications globally.
The Company products are focused on treating Alzheimer’s, chronic migraine, depression, chronic dry eye, elevated intraocular pressure, enlarged prostate, overactive bladder (OAB), irritable bowel syndrome (IBS), cystic fibrosis (CF), retinal disease, post-stroke spasticity, acne and acute bacterial infections, among others. The Company also provides Patient Assistance Program, which provides certain Company's products to patients in the United States who are unable to afford the cost of their medication. Through Patient Assistance Program, the Company provides Armour Thyroid, Linzess, Gelnique, Pylera, Tudorza, AeroChamber Plus Flow-Vu Mouthpiece or Flow-Vu Mask, and Zenpep, among others.
The Company's brand portfolio focuses on the therapeutic categories, including dermatology and aesthetics, central nervous system, eye care, women’s health and urology, gastroenterology and cystic fibrosis, and cardiovascular disease and infectious disease. The Company's brand portfolio consists of products, such as BOTOX, Linzess, RESTASIS, Fetzima, ALPHAGAN P, Asacol HD, JUVEDERM, LATISSE, NATRELLE and Zenpep, among others. The Company manufactures and markets over 1,000 generics, branded generics and over-the-counter (OTC) products. The Company's biosimilar product pipeline includes four oncology products being developed in collaboration with Amgen, including biosimilar versions of Herceptin, Avastin, Rituxan or Mab Thera, and Erbitux.
70 Sir John Rogerson's Quay
Company Web Links
- Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid
- Teva to buy Allergan generic business for $40.5 billion, drops Mylan bid |
- Allergan CEO, fresh off one deal, sets sights on others
- UPDATE 6-Teva to buy Allergan generic business for $40.5 bln, drops Mylan bid
- UPDATE 1-Allergan CEO, fresh off one deal, sets sights on others